“The House’s inclusion of Governor Baker’s proposal to have the state set prescription drug prices in MassHealth is the most severe and consequential piece of legislation for the Massachusetts biotech industry imaginable. If passed, it would rapidly change the face of biotech innovation, scare away investors, and immediately harm patients who are awaiting the next treatment or cure for their disease. The Massachusetts Legislature has the opportunity to take meaningful action on drug pricing this session if they take a considered, collaborative route that rewards for value and increases transparency across the system. Instead, their current approach is to rush through misguided policy with highly questionable fiscal savings estimates through the budget process. We look forward to continuing our dialogue with the House and Senate during this legislative session to develop meaningful solutions that protect patients and protect the innovation that has made Massachusetts the best place in the world for the life sciences.”
– Robert K. Coughlin, President and CEO of MassBio